TIL therapy

About Iovance Biotherapeutics

Iovance Biotherapeutics aims to be the global leader in developing and delivering TIL therapy for cancer patients. The company has achieved a landmark with the first FDA approval of a TIL therapy (Amtagvi/lifileucel) for advanced melanoma and is rapidly expanding into other solid tumors including non-small cell lung cancer (NSCLC), cervical cancer, and endometrial cancer. With a state-of-the-art manufacturing facility and multiple ongoing clinical trials, Iovance is positioned to transform cancer treatment through its personalized cell therapy platform.

About Iovance Biotherapeutics

Iovance Biotherapeutics aims to be the global leader in developing and delivering TIL therapy for cancer patients. The company has achieved a landmark with the first FDA approval of a TIL therapy (Amtagvi/lifileucel) for advanced melanoma and is rapidly expanding into other solid tumors including non-small cell lung cancer (NSCLC), cervical cancer, and endometrial cancer. With a state-of-the-art manufacturing facility and multiple ongoing clinical trials, Iovance is positioned to transform cancer treatment through its personalized cell therapy platform.

Therapeutic Areas